Torii Pharmaceutical Co. Ltd. https://www.torii.co.jp/en/index.html en Notice Regarding Approval of an Additional Dosage and Administration of VTAMA® Cream for Pediatric Atopic Dermatitis (Under Age12) in Japan（PDF） https://www.torii.co.jp/en/release/2026/20260916_E1.pdf 16 Sep 2026 15:00:00 +0900 Announcement of First Dosing in Phase 3 Clinical Study of YCANTH®/TO-208 for the Treatment of Common Warts（PDF） https://www.torii.co.jp/en/release/2026/20260616_E1.pdf 16 Jun 2026 15:30:00 +0900 Positive Interim Analysis Results from Phase 3 Clinical Trial of Tapinarof Cream 0.5%,Aryl Hydrocarbon Receptor (AhR) Modulating Agent,in Infant Patients with Atopic Dermatitis in Japan（PDF） https://www.torii.co.jp/en/release/2026/20260519_E1.pdf 19 May 2026 15:00:00 +0900 " Creating Supportive Workplaces " was updated. https://www.torii.co.jp/en/sustainability/efforts/support.html 07 May 2026 09:00:00 +0900 Announcement Regarding Absorption-Type Merger of Torii by Shionogi & Co., Ltd.（PDF） https://www.torii.co.jp/en/release/2026/20260427_E1.pdf 27 Apr 2026 17:00:00 +0900 Application for Manufacturing and Marketing Approval of a New Lotion Formulation for the Atopic Dermatitis Treatment "CORECTIM®" in Japan（PDF） https://www.torii.co.jp/en/release/2026/20260227_E1.pdf 27 Feb 2026 13:00:00 +0900 Announcement of Decision on Basic Policy Regarding Absorption-Type Merger of Torii by Shionogi & Co., Ltd.（PDF） https://www.torii.co.jp/en/release/2026/20260220_E1.pdf 20 Feb 2026 13:00:00 +0900 Launch of YCANTH® topical solution 0.71% for the Treatment of Molluscum Contagiosum in Japan（PDF） https://www.torii.co.jp/en/release/2026/20260209_E1.pdf 09 Feb 2026 09:00:00 +0900